LivaNova (NASDAQ: LIVN) returns to profit as Q1 2026 revenue climbs

Rhea-AI Filing Summary

LivaNova PLC reported stronger results for the quarter ended March 31, 2026, with net revenue of $362.3 million, up 14.3% from the prior-year period. The company generated net income of $22.3 million, compared with a net loss of $327.3 million a year earlier, when it recorded a large SNIA environmental liability charge.

Cardiopulmonary revenue rose 18.3% to $208.7 million, helped by Essenz Perfusion System sales and consumables demand, while Neuromodulation revenue grew 9.3% to $151.8 million on higher implants and pricing. Operating income declined modestly to $41.5 million as research and development spending increased, including expenses tied to ImThera contingent consideration and sleep apnea device development.

The company ended the quarter with cash and cash equivalents of $539.7 million and total debt of $287.8 million after early repaying $95.9 million under its term facilities. LivaNova recorded a current SNIA environmental liability of $389.5 million and a Saluggia site environmental provision of $41.0 million, and noted it believes it has sufficient resources to satisfy the SNIA obligation.

Insights

Healthcare equity analyst

Revenue grew double digits and profitability normalized, but heavy environmental and contingent obligations remain significant.

LivaNova delivered net revenue of $362.3 million, up 14.3% year over year, with growth in both Cardiopulmonary and Neuromodulation. Cardiopulmonary income benefited from Essenz Perfusion System adoption and consumables, while Neuromodulation growth was offset by higher R&D and ImThera-related contingent consideration.

Operating income of $41.5 million compares with $48.6 million a year ago, but the prior period included a $360.4 million SNIA environmental liability expense that drove a large net loss. The current quarter’s net income of $22.3 million reflects a more typical earnings profile, albeit with higher R&D at 16.2% of revenue.

Liquidity appears solid with $539.7 million in cash and cash equivalents and $225.0 million of undrawn revolving capacity as of March 31, 2026. However, the recorded SNIA environmental liability of $389.5 million, Saluggia site provision of $41.0 million, Italian MedTech payback reserve of $13.3 million, and 3T litigation provision of $12.6 million represent sizable obligations. Future filings may provide additional clarity as the Court of Appeal proceedings and settlement discussions on SNIA progress.

Key Figures

Net revenue: $362.3M Net income: $22.3M Cardiopulmonary revenue: $208.7M +5 more

8 metrics

Net revenue $362.3M Three months ended March 31, 2026

Net income $22.3M Three months ended March 31, 2026

Cardiopulmonary revenue $208.7M Q1 2026 segment revenue, up 18.3% YoY

Neuromodulation revenue $151.8M Q1 2026 segment revenue, up 9.3% YoY

Cash and cash equivalents $539.7M Balance as of March 31, 2026

Total debt $287.8M Including current portion, as of March 31, 2026

SNIA environmental liability $389.5M Current liability as of March 31, 2026

Operating cash flow $15.2M Net cash provided by operating activities, Q1 2026

Key Terms

SNIA environmental liability, ImThera contingent consideration, Italian MedTech payback measure, OBBBA, +1 more

5 terms

SNIA environmental liability financial

"the current liability on the consolidated balance sheet was €337.8 million ($389.5 million)"

ImThera contingent consideration financial

"ImThera business combination involved contingent consideration arrangements comprised of potential cash payments"

Italian MedTech payback measure financial

"introduced a payback measure requiring companies selling medical devices in Italy to repay a percentage"

OBBBA financial

"The OBBBA was enacted in the U.S. on July 4, 2025 and includes significant provisions"

2029 Capped Calls financial

"the Company entered into related privately-negotiated capped call transactions with certain financial institutions"

10-Q Quarterly Reports: What Changes Quarter to Quarter →

false12/312026Q10001639691xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesiso4217:GBPxbrli:sharesxbrli:pureiso4217:EURlivn:claimlivn:segment00016396912026-01-012026-03-3100016396912026-04-2900016396912025-01-012025-03-3100016396912026-03-3100016396912025-12-3100016396912025-01-012025-12-3100016396912024-12-3100016396912025-03-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2026-03-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2025-12-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2026-01-012026-03-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2025-01-012025-03-310001639691livn:A2029NotesMemberlivn:CappedCallMember2024-03-310001639691livn:A2025NotesMemberlivn:CappedCallMember2020-06-300001639691livn:CappedCallMember2020-06-300001639691livn:A2025NotesMemberus-gaap:SeniorNotesMember2024-03-080001639691livn:A2025NotesMemberlivn:CappedCallMember2024-03-082024-03-080001639691livn:A2025NotesMemberlivn:CappedCallMember2025-12-150001639691livn:CappedCallMemberus-gaap:NondesignatedMemberlivn:A2029NotesMember2026-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMemberlivn:A2029NotesMember2026-03-310001639691us-gaap:NondesignatedMember2026-03-310001639691livn:CappedCallMemberus-gaap:NondesignatedMemberlivn:A2029NotesMember2025-12-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMemberlivn:A2029NotesMember2025-12-310001639691us-gaap:NondesignatedMember2025-12-310001639691livn:A2029NotesMemberlivn:CappedCallMember2026-03-310001639691livn:CappedCallMemberus-gaap:FairValueInputsLevel1Memberlivn:A2029NotesMember2026-03-310001639691livn:CappedCallMemberus-gaap:FairValueInputsLevel2Memberlivn:A2029NotesMember2026-03-310001639691livn:CappedCallMemberus-gaap:FairValueInputsLevel3Memberlivn:A2029NotesMember2026-03-310001639691us-gaap:FairValueInputsLevel1Member2026-03-310001639691us-gaap:FairValueInputsLevel2Member2026-03-310001639691us-gaap:FairValueInputsLevel3Member2026-03-310001639691us-gaap:ForeignExchangeContractMember2026-03-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2026-03-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member2026-03-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member2026-03-310001639691livn:A2029NotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2026-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel1Memberlivn:A2029NotesMember2026-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel2Memberlivn:A2029NotesMember2026-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Memberlivn:A2029NotesMember2026-03-310001639691us-gaap:ForeignExchangeContractMember2025-12-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2025-12-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member2025-12-310001639691us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member2025-12-310001639691livn:A2029NotesMemberlivn:CappedCallMember2025-12-310001639691livn:CappedCallMemberus-gaap:FairValueInputsLevel1Memberlivn:A2029NotesMember2025-12-310001639691livn:CappedCallMemberus-gaap:FairValueInputsLevel2Memberlivn:A2029NotesMember2025-12-310001639691livn:CappedCallMemberus-gaap:FairValueInputsLevel3Memberlivn:A2029NotesMember2025-12-310001639691us-gaap:FairValueInputsLevel1Member2025-12-310001639691us-gaap:FairValueInputsLevel2Member2025-12-310001639691us-gaap:FairValueInputsLevel3Member2025-12-310001639691livn:A2029NotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2025-12-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel1Memberlivn:A2029NotesMember2025-12-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel2Memberlivn:A2029NotesMember2025-12-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Memberlivn:A2029NotesMember2025-12-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2029NotesMember2025-12-310001639691us-gaap:NotesReceivableMember2025-12-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2029NotesMember2025-12-310001639691livn:ContingentConsiderationLiabilityMember2025-12-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2029NotesMember2026-01-012026-03-310001639691us-gaap:NotesReceivableMember2026-01-012026-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2029NotesMember2026-01-012026-03-310001639691livn:ContingentConsiderationLiabilityMember2026-01-012026-03-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2029NotesMember2026-03-310001639691us-gaap:NotesReceivableMember2026-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2029NotesMember2026-03-310001639691livn:ContingentConsiderationLiabilityMember2026-03-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2025NotesMember2024-12-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2029NotesMember2024-12-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2025NotesMember2024-12-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2029NotesMember2024-12-310001639691livn:ContingentConsiderationLiabilityMember2024-12-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2025NotesMember2025-01-012025-03-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2029NotesMember2025-01-012025-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2025NotesMember2025-01-012025-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2029NotesMember2025-01-012025-03-310001639691livn:ContingentConsiderationLiabilityMember2025-01-012025-03-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2025NotesMember2025-03-310001639691livn:CappedCallMemberus-gaap:DerivativeFinancialInstrumentsAssetsMemberlivn:A2029NotesMember2025-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2025NotesMember2025-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:EmbeddedExchangeFeatureLiabilityMemberlivn:A2029NotesMember2025-03-310001639691livn:ContingentConsiderationLiabilityMember2025-03-310001639691livn:ContingentConsiderationLiabilityMemberus-gaap:CostOfSalesMember2026-01-012026-03-310001639691livn:ContingentConsiderationLiabilityMemberus-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001639691us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberlivn:A2029NotesMemberus-gaap:MeasurementInputPriceVolatilityMember2026-03-310001639691livn:CappedCallMemberlivn:A2029NotesMemberus-gaap:MeasurementInputPriceVolatilityMember2026-03-310001639691livn:ImTheraMedicalInc.Memberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMember2026-03-310001639691livn:ImTheraMedicalInc.Memberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlivn:MeasurementInputProbabilityofPaymentMember2026-03-310001639691livn:ImTheraMedicalInc.Memberus-gaap:FairValueInputsLevel3Memberus-gaap:MonteCarloModelMemberlivn:MeasurementInputRiskadjustedDiscountRateMember2026-03-310001639691livn:ImTheraMedicalInc.Memberlivn:MeasurementInputCreditRiskDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MonteCarloModelMembersrt:MinimumMember2026-03-310001639691livn:ImTheraMedicalInc.Memberlivn:MeasurementInputCreditRiskDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MonteCarloModelMembersrt:MaximumMember2026-03-310001639691livn:ImTheraMedicalInc.Memberus-gaap:FairValueInputsLevel3Memberus-gaap:MonteCarloModelMemberlivn:MeasurementInputRevenueVolatilityMember2026-03-310001639691livn:ImTheraMedicalInc.Memberus-gaap:FairValueInputsLevel3Memberus-gaap:MonteCarloModelMemberlivn:MeasurementInputProbabilityofPaymentMember2026-03-310001639691livn:ImTheraMedicalInc.Memberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlivn:MeasurementInputProbabilityofPaymentMember2026-01-012026-03-310001639691livn:A2029NotesMemberus-gaap:SeniorNotesMember2026-03-310001639691livn:A2029NotesMemberus-gaap:SeniorNotesMember2025-12-310001639691livn:TermLoanMember2026-03-310001639691livn:TermLoanMember2025-12-310001639691us-gaap:OtherDebtSecuritiesMember2026-03-310001639691us-gaap:OtherDebtSecuritiesMember2025-12-310001639691us-gaap:RevolvingCreditFacilityMember2026-03-310001639691us-gaap:RevolvingCreditFacilityMember2025-12-310001639691us-gaap:RevolvingCreditFacilityMember2024-03-080001639691us-gaap:RevolvingCreditFacilityMember2026-03-310001639691us-gaap:RevolvingCreditFacilityMember2025-12-310001639691us-gaap:RevolvingCreditFacilityMember2026-01-012026-03-310001639691us-gaap:RevolvingCreditFacilityMember2025-01-012025-12-310001639691livn:TermLoanMember2026-01-082026-01-080001639691livn:TermLoanMember2026-01-012026-03-310001639691livn:SaluggiaItalyMember2020-01-012020-12-310001639691livn:SaluggiaItalyMember2026-03-310001639691livn:SaluggiaItalyMembersrt:MaximumMember2026-03-310001639691livn:SaluggiaItalyMember2025-12-310001639691us-gaap:PendingLitigationMemberlivn:SNIAMemberlivn:SNIAs.p.aMember2026-01-012026-03-3100016396912016-01-012016-12-310001639691us-gaap:JudicialRulingMemberlivn:SNIAMember2019-03-310001639691us-gaap:PendingLitigationMemberlivn:SNIAMember2026-03-310001639691us-gaap:JudicialRulingMemberlivn:SNIAMember2021-12-310001639691us-gaap:PendingLitigationMemberlivn:SNIAMemberlivn:SNIAs.p.aMember2026-03-310001639691us-gaap:JudicialRulingMemberlivn:SNIAMemberus-gaap:SuretyBondMember2022-02-012022-02-280001639691us-gaap:JudicialRulingMemberlivn:SNIAMemberus-gaap:SuretyBondMember2026-01-012026-03-310001639691livn:SNIAMember2026-01-012026-03-310001639691livn:SNIAMember2026-03-310001639691us-gaap:SubsequentEventMember2026-05-060001639691livn:ProductLiabilityMember2026-03-310001639691livn:ProductLiabilityMember2025-12-310001639691livn:ProductLiabilityMember2026-01-012026-03-310001639691us-gaap:PendingLitigationMemberlivn:ItalianMedTechPaybackMember2025-09-012025-09-300001639691us-gaap:PendingLitigationMemberlivn:ItalianMedTechPaybackMember2026-01-012026-03-310001639691us-gaap:PendingLitigationMemberlivn:ItalianMedTechPaybackMember2026-03-310001639691us-gaap:PendingLitigationMemberlivn:ItalianMedTechPaybackMember2025-12-310001639691us-gaap:CommonStockMember2025-12-310001639691us-gaap:AdditionalPaidInCapitalMember2025-12-310001639691us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001639691us-gaap:RetainedEarningsMember2025-12-310001639691us-gaap:TreasuryStockCommonMember2025-12-310001639691us-gaap:CommonStockMember2026-01-012026-03-310001639691us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001639691us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001639691us-gaap:RetainedEarningsMember2026-01-012026-03-310001639691us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001639691us-gaap:CommonStockMember2026-03-310001639691us-gaap:AdditionalPaidInCapitalMember2026-03-310001639691us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001639691us-gaap:RetainedEarningsMember2026-03-310001639691us-gaap:TreasuryStockCommonMember2026-03-310001639691us-gaap:CommonStockMember2024-12-310001639691us-gaap:AdditionalPaidInCapitalMember2024-12-310001639691us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001639691us-gaap:RetainedEarningsMember2024-12-310001639691us-gaap:TreasuryStockCommonMember2024-12-310001639691us-gaap:CommonStockMember2025-01-012025-03-310001639691us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001639691us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001639691us-gaap:RetainedEarningsMember2025-01-012025-03-310001639691us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001639691us-gaap:CommonStockMember2025-03-310001639691us-gaap:AdditionalPaidInCapitalMember2025-03-310001639691us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001639691us-gaap:RetainedEarningsMember2025-03-310001639691us-gaap:TreasuryStockCommonMember2025-03-310001639691us-gaap:AccumulatedTranslationAdjustmentMember2025-12-310001639691us-gaap:AccumulatedTranslationAdjustmentMember2026-01-012026-03-310001639691us-gaap:AccumulatedTranslationAdjustmentMember2026-03-310001639691us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001639691us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-03-310001639691us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310001639691livn:ServiceBasedRestrictedStockUnitsMember2026-01-012026-03-310001639691livn:ServiceBasedRestrictedStockUnitsMember2025-01-012025-03-310001639691livn:ServiceBasedStockAppreciationRightsMember2026-01-012026-03-310001639691livn:ServiceBasedStockAppreciationRightsMember2025-01-012025-03-310001639691livn:MarketbasedPerformanceRestrictedStockUnitsMember2026-01-012026-03-310001639691livn:MarketbasedPerformanceRestrictedStockUnitsMember2025-01-012025-03-310001639691livn:PerformanceBasedRestrictedShareAndRestrictedShareUnitMember2026-01-012026-03-310001639691livn:PerformanceBasedRestrictedShareAndRestrictedShareUnitMember2025-01-012025-03-310001639691us-gaap:EmployeeStockMember2026-01-012026-03-310001639691us-gaap:EmployeeStockMember2025-01-012025-03-310001639691livn:ServiceBasedRestrictedStockUnitsMember2026-03-310001639691us-gaap:PerformanceSharesMember2026-01-012026-03-310001639691us-gaap:PerformanceSharesMember2026-03-310001639691srt:MinimumMemberus-gaap:PerformanceSharesMember2026-01-012026-03-310001639691srt:MaximumMemberus-gaap:PerformanceSharesMember2026-01-012026-03-310001639691us-gaap:StockCompensationPlanMember2026-01-012026-03-310001639691us-gaap:StockCompensationPlanMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMembercountry:USlivn:CardiopulmonarySegmentMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMembercountry:USlivn:CardiopulmonarySegmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMembersrt:EuropeMemberlivn:CardiopulmonarySegmentMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMembersrt:EuropeMemberlivn:CardiopulmonarySegmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMemberlivn:LocationsExcludingTheUnitedStatesAndEuropeMemberlivn:CardiopulmonarySegmentMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMemberlivn:LocationsExcludingTheUnitedStatesAndEuropeMemberlivn:CardiopulmonarySegmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMemberlivn:CardiopulmonarySegmentMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMemberlivn:CardiopulmonarySegmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMembercountry:USlivn:NeuromodulationSegmentMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMembercountry:USlivn:NeuromodulationSegmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMembersrt:EuropeMemberlivn:NeuromodulationSegmentMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMembersrt:EuropeMemberlivn:NeuromodulationSegmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMemberlivn:LocationsExcludingTheUnitedStatesAndEuropeMemberlivn:NeuromodulationSegmentMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMemberlivn:LocationsExcludingTheUnitedStatesAndEuropeMemberlivn:NeuromodulationSegmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMemberlivn:NeuromodulationSegmentMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMemberlivn:NeuromodulationSegmentMember2025-01-012025-03-310001639691us-gaap:CorporateNonSegmentMember2026-01-012026-03-310001639691us-gaap:CorporateNonSegmentMember2025-01-012025-03-310001639691country:US2026-01-012026-03-310001639691country:US2025-01-012025-03-310001639691srt:EuropeMember2026-01-012026-03-310001639691srt:EuropeMember2025-01-012025-03-310001639691livn:LocationsExcludingTheUnitedStatesAndEuropeMember2026-01-012026-03-310001639691livn:LocationsExcludingTheUnitedStatesAndEuropeMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMember2026-01-012026-03-310001639691us-gaap:OperatingSegmentsMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMemberlivn:CardiopulmonarySegmentMember2026-03-310001639691us-gaap:OperatingSegmentsMemberlivn:CardiopulmonarySegmentMember2025-12-310001639691us-gaap:OperatingSegmentsMemberlivn:NeuromodulationSegmentMember2026-03-310001639691us-gaap:OperatingSegmentsMemberlivn:NeuromodulationSegmentMember2025-12-310001639691us-gaap:CorporateNonSegmentMember2026-03-310001639691us-gaap:CorporateNonSegmentMember2025-12-310001639691livn:CardiopulmonarySegmentMember2025-12-310001639691livn:NeuromodulationSegmentMember2025-12-310001639691livn:CardiopulmonarySegmentMember2026-01-012026-03-310001639691livn:NeuromodulationSegmentMember2026-01-012026-03-310001639691livn:CardiopulmonarySegmentMember2026-03-310001639691livn:NeuromodulationSegmentMember2026-03-310001639691country:US2026-03-310001639691country:US2025-12-310001639691srt:EuropeMember2026-03-310001639691srt:EuropeMember2025-12-310001639691livn:LocationsExcludingTheUnitedStatesAndEuropeMember2026-03-310001639691livn:LocationsExcludingTheUnitedStatesAndEuropeMember2025-12-310001639691livn:A2029NotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2026-01-012026-03-310001639691livn:A2029NotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2025-01-012025-03-310001639691livn:A2029NotesMemberlivn:CappedCallMember2026-01-012026-03-310001639691livn:A2029NotesMemberlivn:CappedCallMember2025-01-012025-03-310001639691livn:A2025NotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2026-01-012026-03-310001639691livn:A2025NotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2025-01-012025-03-310001639691livn:A2025NotesMemberlivn:CappedCallMember2026-01-012026-03-310001639691livn:A2025NotesMemberlivn:CappedCallMember2025-01-012025-03-310001639691srt:ScenarioPreviouslyReportedMember2025-01-012025-03-310001639691srt:RestatementAdjustmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMembersrt:ScenarioPreviouslyReportedMemberlivn:CardiopulmonarySegmentMember2025-01-012025-03-310001639691us-gaap:OperatingSegmentsMembersrt:RestatementAdjustmentMemberlivn:CardiopulmonarySegmentMember2025-01-012025-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

Form 10-Q

(Mark One)

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission file number: 001-37599

LivaNova PLC

(Exact name of registrant as specified in its charter)

England and Wales ................... 98-1268150

(State or other jurisdiction of .......... (I.R.S. Employer

incorporation or organization) ........ Identification No.)

20 Eastbourne Terrace, London, United Kingdom, W2 6LG

(Address of principal executive offices) ....................... (Zip Code)

Registrant’s telephone number, including area code: (44) (0) 203 325-0660

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary Shares - £1.00 par value per share

LIVN

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer			☑			Accelerated filer			☐
Non-accelerated filer			☐			Smaller reporting company			☐
Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

Class			Outstanding on April 29, 2026
Ordinary Shares - £1.00 par value per share			54,933,538

LIVANOVA PLC

TABLE OF CONTENTS

Item						Description						Page
						Definitions						1
						Intellectual Property, Trademarks, and Trade Names						3
						Cautionary Note About Forward-Looking Statements						4
						PART I. FINANCIAL INFORMATION
1.						Financial Statements (unaudited)						5
2.						Management’s Discussion and Analysis of Financial Condition and Results of Operations						24
3.						Quantitative and Qualitative Disclosures About Market Risk						29
4.						Controls and Procedures						29
						PART II. OTHER INFORMATION
1.						Legal Proceedings						31
1A.						Risk Factors						31
2.						Unregistered Sales of Equity Securities and Use of Proceeds						31
3.						Defaults Upon Senior Securities						31
4.						Mine Safety Disclosures						31
5.						Other Information						31
6.						Exhibits						32
						Signatures						33

DEFINITIONS

In this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the following terms and abbreviations have the meanings listed below. “LivaNova” and the “Company” refer to LivaNova PLC and its consolidated subsidiaries.

Abbreviation						Definition
2016 Decision						Decision by the Court of Milan in 2016 to dismiss all legal actions of SNIA and of the Public Administrations and to further require the Public Administrations to pay Sorin €292,000 for legal fees
2021 First Lien Credit Agreement						First Lien Credit Agreement between LivaNova PLC and its wholly-owned subsidiary, LivaNova USA, Inc., and Goldman Sachs Bank USA, as First Lien Administrative Agent and First Lien Collateral Agent, entered into on August 13, 2021
2025 Capped Calls						Privately-negotiated capped call transactions entered into with certain financial institutions
2025 Embedded Derivative						The bifurcated embedded derivative associated with the 2025 Notes
2025 Form 10-K						LivaNova PLC’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 25, 2026
2025 Notes						$287.5 million aggregate principal amount 3.00% unsecured cash exchangeable senior notes due December 15, 2025, by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova USA on June 17, 2020
2029 Capped Calls						Privately-negotiated capped call transactions entered into with certain financial institutions
2029 Embedded Derivative						The bifurcated embedded derivative associated with the 2029 Notes
2029 Notes						$345.0 million aggregate principal amount 2.50% unsecured convertible senior notes due 2029 by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova PLC on March 8, 2024
AOCI						Accumulated other comprehensive income (loss)
ASU						Accounting Standards Update
CEO						Chief Executive Officer
CFO						Chief Financial Officer
CODM						Chief Operating Decision Maker
Court of Appeal						Court of Appeal in Milan
Delayed Draw Term Facility						$50.0 million delayed draw term facility under the 2021 First Lien Credit Agreement, resulting from the Incremental Facility Amendment No. 2
DRE						Drug-resistant epilepsy
DTD						Difficult-to-treat Depression - The Company’s broader business and strategic communications reference DTD as the preferred disease state when speaking more broadly about depression treatment, as it is a more inclusive and clinically evolving concept that encompasses patients whose depression continues to cause significant burden despite usual treatment efforts. Meanwhile, LivaNova’s RECOVER clinical study defines the patient population using the inclusion criteria for TRD, typically characterized by major depressive disorder that does not adequately respond to at least two different antidepressant treatments given at an appropriate dose and duration. As a result, the Company uses TRD in the context of the RECOVER study to maintain consistency with the study protocol approved by the U.S. Centers for Medicare & Medicaid Services. References to either term in this filing are context-dependent but describe overlapping populations.
ECJ						European Court of Justice
Embedded Derivatives						The bifurcated embedded derivatives associated with the 2025 Notes and 2029 Notes, collectively
Exchange Act						U.S. Securities Exchange Act of 1934, as amended
FASB						Financial Accounting Standards Board
FDA						U.S. Food and Drug Administration
FX						Foreign currency exchange rate
HLM						Heart-lung machine
ImThera						ImThera Medical, Inc. was a company developing an implantable neurostimulation device system for the treatment of obstructive sleep apnea that LivaNova acquired in 2018
Incremental Facility Amendment No. 2						An incremental facility amendment to the 2021 First Lien Credit Agreement, dated July 6, 2022

1

Abbreviation						Definition
Incremental Facility Amendment No. 3						An incremental facility amendment to the 2021 First Lien Credit Agreement, dated March 8, 2024
Initial Term Facility						$300.0 million term facility under the 2021 First Lien Credit Agreement, resulting from the Incremental Facility Amendment No. 2
ISIN						National Inspectorate for Nuclear Safety and Radiation Protection, a sub-body of the Italian Ministry of Economic Development
LivaNova PLC						A public limited company organized under the laws of England and Wales on February 20, 2015
LivaNova USA						LivaNova USA, Inc.
LSM						LivaNova Site Management S.r.l.
MedTech						Medical technology
Nasdaq						Nasdaq Global Select Market
OBBBA						One Big Beautiful Bill Act
OSA						Obstructive sleep apnea
PMA						Premarket approval
Public Administrations						The Italian Ministry of the Environment and other Italian government agencies
R&D						Research and development
Report						This Quarterly Report on Form 10-Q
RSU						Restricted stock unit
SAR						Stock appreciation right
SEC						U.S. Securities and Exchange Commission
Securities Act						U.S. Securities Act of 1933, as amended
SG&A						Selling, general, and administrative
SNIA						SNIA S.p.A.
SNIA Litigation Guarantee						A first demand bank guarantee of €270.0 million in connection with the SNIA environmental litigation
Sorin						Sorin S.p.A.
Term Facilities						The Initial Term Facility, together with the Delayed Draw Term Facility
TRD						Treatment-resistant Depression - LivaNova’s RECOVER clinical study defines the patient population using the inclusion criteria for TRD, typically characterized by major depressive disorder that does not adequately respond to at least two different antidepressant treatments given at an appropriate dose and duration. As a result, the Company uses TRD in the context of the RECOVER study to maintain consistency with the study protocol approved by the U.S. Centers for Medicare and Medicaid Services. Meanwhile, the Company’s broader business and strategic communications reference DTD as the preferred disease state when speaking more broadly about depression treatment, as it is a more inclusive and clinically evolving concept that encompasses patients whose depression continues to cause significant burden despite usual treatment efforts. References to either term in this filing are context-dependent but describe overlapping populations.
U.S.						United States of America
U.S. GAAP						Generally Accepted Accounting Principles in the U.S.
UK						United Kingdom
USD						U.S. dollar
VNS Therapy						LivaNova Vagus Nerve Stimulation Therapy

2

INTELLECTUAL PROPERTY, TRADEMARKS, AND TRADE NAMES

This Report may contain references to LivaNova’s proprietary intellectual property, including among others:

•Trademarks for LivaNova’s Neuromodulation systems, the VNS Therapy™ System, and LivaNova’s proprietary pulse generator products: Model 102 (Pulse™), Model 102R (Pulse Duo™), Model 103 (Demipulse™), Model 104 (Demipulse Duo™), Model 106 (AspireSR™), Model 1000 (SenTiva™), Model 1000-D (SenTiva™ Duo), and Model 8103 (Symmetry™).

•Trademarks for LivaNova’s Cardiopulmonary products and systems: Essenz™, S5™, S5 Pro™, B-Capta™, Inspire™, Heartlink™, XTRA™, 3T Heater-Cooler™, Connect™, Revolution™, ProtekDuo™, and TandemHeart™.

•Trademarks for LivaNova’s obstructive sleep apnea system: ImThera™, aura6000™, and PolySync™.

These trademarks and trade names are the property of LivaNova or the property of LivaNova’s consolidated subsidiaries and are protected under applicable intellectual property laws. Solely for convenience, LivaNova’s trademarks and trade names referred to in this Report may appear without the ™ symbol, but such references are not intended to indicate in any way that the Company will not assert, to the fullest extent under applicable law, LivaNova’s rights to these trademarks and trade names.

3

CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS

Certain statements in this Report, other than statements of historical or current fact, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects, or future events, and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. Generally, forward-looking statements can be identified by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and shareholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from the forward-looking statements contained in this Report, and include, but are not limited to, the following risks and uncertainties: volatility in the global market and worldwide economic conditions; adverse changes in export and import costs and other trade restrictions as well as uncertainty over global tariffs; risks relating to supply chain pressures; failure to protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption; costs of complying with privacy and security of personal information requirements and laws; changes in technology, including the development of superior or alternative technology or devices by competitors and/or competition from providers of alternative medical therapies; risks related to AI integration and regulation; failure of investments, alliances, acquisitions, or divestitures to achieve expected returns; failure to maintain appropriate working relationships with healthcare professionals to aid in the continuing development of products; the risk of quality issues and the impacts thereof; risks relating to recalls, replacement of inventory, enforcement actions, or product liability claims; failure to comply with, or changes in, laws, regulations, or administrative practices affecting government regulation of the Company’s products; failure to retain talent, maintain an effective succession plan, and negotiate successfully with local works councils; failure to obtain or maintain approvals, clearance, or reimbursement in relation to the Company’s products; unfavorable results from clinical studies or failure to meet milestones; global healthcare policy changes that may lead to restricted access and pricing as well as payback requirements and limited reimbursement; failure to comply with rules relating to healthcare goods and services as well as anti-bribery laws; the unfavorable impact of pending or existing climate change; product liability, intellectual property, shareholder-related, environmental-related, income tax, and other litigation, disputes, losses, and costs, including in the case of the Company’s 3T Heater-Cooler litigation; risks associated with environmental laws and regulations as well as environmental liabilities, violations, and litigation, including in the case of Saluggia and SNIA; failure to protect the Company’s proprietary intellectual property; changes in tax laws and regulations, including exposure to additional income tax liabilities; risks relating to the Company’s indebtedness; risks associated with potential government shutdowns; the potential for impairments of intangible assets, goodwill, and other long-lived assets; risks associated with public health crises; risks associated with shareholder activism; effectiveness of the Company’s internal controls over financial reporting; changes in the Company’s profitability and/or failure to manage costs and expenses; fluctuations in future quarterly operating results and/or variations in revenue and operating expenses relative to estimates; and other unknown or unpredictable factors that could harm the Company’s financial performance.

Other factors that could cause LivaNova’s actual results to differ from projected results are described in: (1) “Part II, Item 1A. Risk Factors” and elsewhere in this Report and the Company’s other Quarterly Reports on Form 10-Q, (2) the Company’s 2025 Form 10-K, (3) the Company’s reports and registration statements filed with and furnished from time to time to the SEC, and (4) other announcements LivaNova makes from time to time.

Readers are cautioned not to place undue reliance on the Company’s forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events, or otherwise. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and related notes included elsewhere in this Report. Operating results for the three months ended March 31, 2026 are not necessarily indicative of future results, including the full fiscal year. Also refer to the Company’s “Annual Consolidated Financial Statements,” “Notes” thereto, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Risk Factors” contained in LivaNova’s 2025 Form 10-K and in the Company’s Quarterly Reports on Form 10-Q.

Financial Information and Currency of Financial Statements

All of the financial information included in this Report has been prepared in accordance with U.S. GAAP. The reporting currency of the Company’s condensed consolidated financial statements is USD.

4

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

LIVANOVA PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(UNAUDITED)

(In thousands, except per share amounts)

												Three Months Ended March 31,
																		2026						2025
Net revenue																		$	362,258					$	316,855
Cost of sales																		118,509						100,601
Gross profit																		243,749						216,254
Operating expenses:
Selling, general, and administrative																		143,568						129,146
Research and development																		58,695						37,879
Other operating expense																		15						612
Operating income																		41,471						48,617
SNIA environmental liability expense																		—						(360,393)
Interest expense																		(8,291)						(15,286)
Foreign exchange and other income/(expense)																		(5,695)						11,416
Income (loss) before income tax																		27,485						(315,646)
Income tax expense																		4,340						11,656
Loss from equity method investments																		(851)						(20)
Net income (loss)																		$	22,294					$	(327,322)
Basic earnings (loss) per share																		$	0.41					$	(6.01)
Diluted earnings (loss) per share																		$	0.40					$	(6.01)
Basic weighted average shares outstanding																		54,688						54,421
Diluted weighted average shares outstanding																		55,944						54,421

See accompanying notes to the condensed consolidated financial statements.

5

LIVANOVA PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(In thousands)

												Three Months Ended March 31,
																		2026						2025
Net income (loss)																		$	22,294					$	(327,322)
Other comprehensive (loss) income
Foreign currency translation adjustments																		(10,731)						37,442
Total other comprehensive (loss) income																		(10,731)						37,442
Total comprehensive income (loss)																		$	11,563					$	(289,880)

See accompanying notes to the condensed consolidated financial statements.

6

LIVANOVA PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except share amounts)

						March 31, 2026						December 31, 2025
ASSETS
Current Assets:
Cash and cash equivalents						$	539,706					$	635,552
Accounts receivable, net of allowance of $10,309 as of March 31, 2026 and $12,527 as of December 31, 2025						229,273						215,985
Inventories						165,504						164,701
Prepaid and refundable taxes						41,272						48,606
Prepaid expenses and other current assets						38,482						36,769
Total Current Assets						1,014,237						1,101,613
Property, plant, and equipment, net						255,483						242,603
Goodwill						785,590						792,840
Intangible assets, net						224,556						229,964
Operating lease assets						54,532						55,519
Investments						18,492						20,291
Deferred tax assets						109,816						110,983
Long-term derivative assets						38,277						36,551
Other assets						15,368						15,689
Total Assets						$	2,516,351					$	2,606,053
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Current debt obligations						$	2,628					$	31,472
Accounts payable						99,148						97,157
Accrued liabilities and other						102,649						94,573
SNIA environmental liability						389,485						396,242
Current contingent consideration						59,589						50,030
Current litigation provision liability						9,643						12,552
Taxes payable						41,704						33,133
Accrued employee compensation and related benefits						57,632						92,913
Total Current Liabilities						762,478						808,072
Long-term debt obligations						285,160						345,185
Long-term contingent consideration						43,141						42,045
Deferred tax liabilities						6,812						9,590
Long-term operating lease liabilities						46,696						48,327
Long-term employee compensation and related benefits						13,105						13,574
Long-term derivative liabilities						93,254						83,904
Other long-term liabilities						54,379						55,369
Total Liabilities						1,305,025						1,406,066
Commitments and contingencies (Note 5)
Shareholders’ Equity:
Ordinary Shares, £1.00 par value: Unlimited shares authorized; 55,537,746 shares issued and 54,901,316 shares outstanding as of March 31, 2026; 55,535,181 shares issued and 54,649,085 shares outstanding as of December 31, 2025						84,564						84,564
Additional paid-in capital						2,254,756						2,254,980
Accumulated other comprehensive (loss) income						(3,401)						7,330
Accumulated deficit						(1,123,427)						(1,145,721)
Treasury shares at cost, 636,430 ordinary shares as of March 31, 2026; 886,096 ordinary shares as of December 31, 2025						(1,166)						(1,166)
Total Shareholders’ Equity						1,211,326						1,199,987
Total Liabilities and Shareholders’ Equity						$	2,516,351					$	2,606,053

See accompanying notes to the condensed consolidated financial statements.

7

LIVANOVA PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In thousands)

						Three Months Ended March 31,
						2026						2025
Operating Activities:
Net income (loss)						$	22,294					$	(327,322)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Remeasurement of contingent consideration to fair value						10,655						922
Remeasurement of derivative instruments						9,795						(18,717)
Depreciation						8,300						6,419
Share-based compensation						8,270						7,783
Amortization of debt issuance costs						4,769						5,676
Amortization of intangible assets						4,563						4,215
Amortization of operating lease assets						2,732						4,037
Deferred income tax expense						1,824						2,244
Impairments of investments						1,132						—
Loss on investment revaluation - Ceribell, Inc.						—						2,614
Other						1,174						11
Changes in operating assets and liabilities:
Accounts receivable, net						(14,669)						(3,896)
Inventories						(1,546)						(2,494)
Other current and non-current assets						(4,199)						6,437
Accounts payable and accrued current and non-current liabilities						(38,771)						(30,516)
Taxes payable						1,713						5,934
Litigation provision liability						(2,820)						226
SNIA environmental liability						—						360,393
Net cash provided by operating activities						15,216						23,966
Investing Activities:
Purchases of property, plant, and equipment						(14,290)						(10,790)
Other						(290)						162
Net cash used in investing activities						(14,580)						(10,628)
Financing Activities:
Repayment of long-term debt obligations						(95,938)						(4,375)
Other						1,693						(46)
Net cash used in financing activities						(94,245)						(4,421)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash						(2,237)						5,964
Net (decrease) increase in cash, cash equivalents, and restricted cash						(95,846)						14,881
Cash, cash equivalents, and restricted cash at beginning of period						635,552						723,556
Cash and cash equivalents at end of period						$	539,706					$	738,437
Supplemental noncash investing and financing transactions:
Capital expenditures included in accounts payable						$	10,461					$	2,379

See accompanying notes to the condensed consolidated financial statements.

8

LIVANOVA PLC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Unaudited Condensed Consolidated Financial Statements

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of LivaNova and the notes thereto as of and for the three months ended March 31, 2026 and 2025 have been prepared in accordance with U.S. GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying condensed consolidated balance sheet of LivaNova as of December 31, 2025 has been derived from audited consolidated financial statements contained in LivaNova’s 2025 Form 10-K but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments considered necessary for a fair statement of the operating results of LivaNova and its subsidiaries for the three months ended March 31, 2026, and are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. The financial information presented herein should be read in conjunction with the audited consolidated financial statements and notes thereto accompanying LivaNova’s 2025 Form 10-K.

Revision of Previously Issued Financial Statements

During the second quarter of 2025, the Company identified and corrected an immaterial error related to the classification of certain employee costs in the Cardiopulmonary segment between cost of sales and selling, general, and administrative expense in the consolidated statements of income (loss). This misclassification understated cost of sales and overstated selling, general, and administrative expense by equal and offsetting amounts, with no impact to operating income (loss) or net income (loss) for the three months ended March 31, 2025. The Company evaluated the error and determined that the related impact was not material to the consolidated statements of income (loss) for any prior period and had no impact on the consolidated balance sheets, statements of comprehensive income (loss), statements of cash flows, or statements of shareholders’ equity for the above period. The Company has revised the previously issued condensed consolidated statements of income (loss) for the three months ended March 31, 2025 to correct for the error, and these revisions are reflected in this Form 10-Q. A summary of the corrections to the impacted financial statement line items in the previously issued consolidated statements of income (loss) and disaggregated Cardiopulmonary segment income disclosure for each affected period is presented in “Note 13. Revision of Previously Issued Financial Statements.”

Significant Accounting Policies

LivaNova’s significant accounting policies are included within “Note 2. Basis of Presentation, Use of Accounting Estimates, and Significant Accounting Policies” and “Note 3. Revenue Recognition” of LivaNova’s 2025 Form 10-K.

Note 2. Derivatives and Risk Management

Due to the global nature of LivaNova’s operations, the Company is exposed to FX fluctuations. LivaNova enters into FX derivative contracts to reduce the impact of FX fluctuations on earnings and cash flow.

LivaNova is also exposed to equity price risk in connection with its 2029 Notes, including exchange/conversion and settlement provisions based on the price of its ordinary shares at exchange/conversion or maturity of the 2029 Notes. The 2029 Capped Calls associated with the 2029 Notes also include settlement provisions that are based on the price of LivaNova’s ordinary shares, subject to a capped price per share.

These derivatives are intended to serve as economic hedges and follow the cash flows of the economic hedged item. LivaNova does not enter into derivative contracts for speculative purposes.

LivaNova had no designated hedging instruments as of March 31, 2026 and December 31, 2025.

Freestanding FX Derivatives

LivaNova uses freestanding derivative forward contracts to offset the variability of the value associated with intercompany loans denominated in a foreign currency. The gross notional amount of freestanding FX derivative contracts outstanding as of March 31, 2026 and December 31, 2025 was $128.2 million and $113.2 million, respectively. LivaNova recorded net losses of $2.2 million for the three months ended March 31, 2026 and net gains of $10.4 million for the three months ended March 31, 2025 from freestanding derivatives. These amounts, together with foreign currency remeasurement gains and losses on the underlying intercompany loans, are included in foreign exchange and other income/(expense) in LivaNova’s condensed consolidated statements of income (loss).

9

Capped Call Derivatives

The Capped Call Transactions are carried on the condensed consolidated balance sheets as a derivative asset at their estimated fair value and are adjusted at the end of each reporting period, with unrealized gain or loss reflected in foreign exchange and other income/(expense) in the condensed consolidated statements of income (loss). The Capped Call Transactions are measured at fair value using the Black-Scholes model utilizing observable and unobservable market data, including share price, remaining contractual term, expected volatility, risk-free interest rate, and expected dividend yield, as applicable. For additional information, refer to “Note 3. Fair Value Measurements,” and “Note 11. Supplemental Financial Information.”

2029 Capped Calls

In March 2024, LivaNova issued the 2029 Notes. In connection with the pricing of the 2029 Notes, the Company entered into related privately-negotiated capped call transactions with certain financial institutions. Under the 2029 Capped Calls, the Company purchased a capped call option with an initial strike price of $69.40 and an initial cap price of $94.28 per share. The strike price, which is subject to certain adjustments, corresponds to the initial conversion price of the 2029 Notes. The 2029 Capped Calls are intended to offset any cash payments and/or cash equivalent value of ordinary shares upon conversion of the 2029 Notes if the market value per ordinary share is greater than the strike price, with such offsets being subject to the initial cap price of $94.28 per share. However, the proceeds under the 2029 Capped Calls are limited to the initial cap price in the event the Company’s share price exceeds the cap price at the time of conversion. The 2029 Capped Calls expire on March 15, 2029, and must be settled in cash. The 2029 Capped Calls are subject to anti-dilution adjustments substantially similar to those applicable to the 2029 Notes and cover the number of LivaNova’s ordinary shares underlying the 2029 Notes. If the 2029 Capped Calls are terminated early, settlement occurs at their termination value, which is equal to their fair value at the time of the early termination.

2025 Capped Calls

In June 2020, LivaNova issued the 2025 Notes. In connection with the pricing of the 2025 Notes, the Company entered into related privately-negotiated capped call transactions with certain financial institutions. Under the 2025 Capped Calls, the Company purchased a capped call option with an initial strike price of $60.98 and an initial cap price of $100.00 per share. The strike price, subject to certain adjustments, corresponds to the initial exchange price of the 2025 Notes. The 2025 Capped Calls were intended to offset any cash payments upon exchange of the 2025 Notes in excess of the principal amount. In connection with the issuance of the 2029 Notes, the Company repurchased an aggregate principal amount of $230.0 million of the 2025 Notes and unwound a corresponding portion of the 2025 Capped Calls at the fair value of such portion of the 2025 Capped Calls. The Company received $22.5 million in cash consideration, the fair value of the terminated portion, upon settlement. The remaining 2025 Capped Calls expired with a fair value of zero on December 15, 2025.

Embedded Derivatives

The 2025 Notes included, and the 2029 Notes include, terms resulting in a bifurcated embedded derivative. The Embedded Derivatives are measured at fair value using a binomial lattice model and estimated discounted cash flows that utilize observable and unobservable market data and are adjusted at the end of each reporting period, with the unrealized gain or loss reflected in foreign exchange and other income/(expense) in the condensed consolidated statements of income (loss). For additional information, refer to “Note 11. Supplemental Financial Information.”

Balance Sheet Presentation

LivaNova offsets fair value amounts associated with its derivative instruments that are executed with the same counterparty under master netting arrangements on the Company’s condensed consolidated balance sheets. Master netting arrangements include a right to set off or net together purchases and sales of similar products in the settlement process.

10

The following tables present the fair value and the location of derivative contracts reported on the condensed consolidated balance sheets (in thousands):

Derivative Assets

Derivative Liabilities

March 31, 2026

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives Not Designated as Hedging Instruments:

2029 Capped Calls

Long-term derivative assets

$

38,277

2029 Embedded Derivative

Long-term derivative liabilities

$

93,254

FX derivative contracts

Accrued liabilities and other

613

Total derivatives not designated as hedging instruments

$

38,277

$

93,867

Derivative Assets

Derivative Liabilities

December 31, 2025

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives Not Designated as Hedging Instruments:

2029 Capped Calls

Long-term derivative assets

$

36,551

2029 Embedded Derivative

Long-term derivative liabilities

$

83,904

FX derivative contracts

Prepaid expenses and other current assets

165

Accrued liabilities and other

99

Total derivatives not designated as hedging instruments

$

36,716

$

84,003

Note 3. Fair Value Measurements

LivaNova reviews its fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities in the fair value hierarchy. There were no transfers between Level 1, Level 2, or Level 3 for the three months ended March 31, 2026 and 2025.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables present the level in the fair value hierarchy at which the Company’s assets and liabilities are measured on a recurring basis (in thousands):

												Total						Fair Value Measurements Using Inputs Considered as:
March 31, 2026															Level 1						Level 2						Level 3
Assets:
Derivative assets - 2029 Capped Calls												$	38,277					$	—					$	—					$	38,277
Investment in convertible notes receivable												3,000						—						—						3,000
												$	41,277					$	—					$	—					$	41,277
Liabilities:
Derivative liabilities - freestanding instruments (FX)												$	613					$	—					$	613					$	—
Derivative liabilities - 2029 Embedded Derivative												93,254						—						—						93,254
ImThera contingent consideration arrangements												102,730						—						—						102,730
												$	196,597					$	—					$	613					$	195,984

11

												Total						Fair Value Measurements Using Inputs Considered as:
December 31, 2025															Level 1						Level 2						Level 3
Assets
Derivative assets - freestanding instruments (FX)												$	165					$	—					$	165					$	—
Derivative assets - 2029 Capped Calls												36,551						—						—						36,551
Investment in convertible notes receivable												3,000						—						—						3,000
												$	39,716					$	—					$	165					$	39,551
Liabilities
Derivative liabilities - freestanding instruments (FX)												$	99					$	—					$	99					$	—
Derivative liabilities - 2029 Embedded Derivative												83,904						—						—						83,904
ImThera contingent consideration arrangements												92,075						—						—						92,075
												$	176,078					$	—					$	99					$	175,979

Reconciliation of Level 3 Assets and Liabilities

The tables below present reconciliations of recurring fair value measurements that use significant unobservable inputs (Level 3) (in thousands):

						Derivative Assets - 2029 Capped Calls (1)						Investment in Convertible Notes Receivable						Derivative Liabilities - 2029 Embedded Derivative (1)						ImThera Contingent Consideration Arrangements Liability
December 31, 2025						$	36,551					$	3,000					$	83,904					$	92,075
Changes in fair value (2)						1,726						—						9,350						10,655
March 31, 2026						$	38,277					$	3,000					$	93,254					$	102,730

						Derivative Assets - 2025 Capped Calls (1)						Derivative Assets - 2029 Capped Calls (1)						Derivative Liabilities - 2025 Embedded Derivative (1)						Derivative Liabilities - 2029 Embedded Derivative (1)						ImThera Contingent Consideration Arrangements Liability
December 31, 2024						$	2,624					$	23,735					$	2,915					$	51,819					$	84,218
Changes in fair value (2)						(1,819)						(6,545)						(2,041)						(14,593)						922
March 31, 2025						$	805					$	17,190					$	874					$	37,226					$	85,140

(1)Gains and losses are recorded in foreign exchange and other income/(expense) in the condensed consolidated statements of income (loss).

(2)For the three months ended March 31, 2026, the contingent consideration change in fair value resulted in an increase of $1.1 million recorded to cost of sales and an increase of $9.6 million recorded to R&D. For the three months ended March 31, 2025, the contingent consideration change in fair value was primarily recorded to R&D.

Share Price Volatility

The share price volatility utilized in determining the fair value of LivaNova’s 2029 Capped Call derivative assets and 2029 Embedded Derivative liability as of March 31, 2026 was 39%. In general, an increase in LivaNova’s share price or share price volatility would increase the fair value of the embedded and capped call derivatives, which would result in an increase in net expense. As the remaining time to the expiration of the derivatives decreases, the fair value of the derivatives decreases. The future impact of the derivatives on net income (loss) depends on how significant inputs, such as share price volatility, and time to the expiration of the derivatives, change in relation to other inputs.

Contingent Consideration Arrangements

The ImThera business combination involved contingent consideration arrangements comprised of potential cash payments upon the achievement of a certain regulatory milestone and a sales-based earnout associated with sales of products. The sales-based

12

earnouts are valued using projected sales from LivaNova’s internal strategic plan. These arrangements are Level 3 fair value measurements and include the following significant unobservable inputs as of March 31, 2026:

ImThera Acquisition

Valuation Technique

Unobservable Input

Inputs

Regulatory milestone-based payment

Discounted cash flow

Discount rate

6.9%

Probability of payment (1)

100%

Projected payment year

2026

Sales-based earnout

Monte-Carlo simulation

Risk-adjusted discount rate

11.7%

Credit risk discount rate

7.4% - 7.7%

Revenue volatility

22.8%

Probability of payment

95%

Projected payment years

2028 - 2029

(1)In March 2026, the Company achieved the regulatory milestone upon PMA by the FDA. As a result, the probability of payment was increased to 100% and will be paid within 90 days of milestone achievement.

Other

The carrying value of LivaNova’s long-term debt including the current portion as of March 31, 2026 and December 31, 2025 was $285.3 million and $376.1 million, respectively. The fair value of the 2029 Notes, excluding the conversion feature, as of March 31, 2026 and December 31, 2025 was $306.0 million and $315.2 million, respectively. The fair value was estimated using a discounted cash flow model and is classified as Level 2 within the fair value hierarchy. For all other long-term debt obligations, LivaNova believes the carrying value approximates fair value. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

Note 4. Financing Arrangements

The following table presents a summary of LivaNova’s long-term debt obligations (in thousands):

						March 31, 2026						December 31, 2025						Maturity						Interest Rate
2029 Notes						$	280,172					$	275,599					March 2029						2.50%
Term Facilities						—						95,063
Other						5,109						5,401
Total long-term debt						285,281						376,063
Less: Current portion of long-term debt						121						30,878
Total long-term debt obligations						$	285,160					$	345,185

Revolving Credit and Term Facilities

The outstanding principal amount of LivaNova’s short-term unsecured revolving credit agreements and other agreements with various banks was $2.5 million and $0.6 million as of March 31, 2026 and December 31, 2025, respectively, with an interest rate of 5.33% as of March 31, 2026.

On March 8, 2024, LivaNova and LivaNova USA entered into Incremental Facility Amendment No. 3, which provides for LivaNova USA to obtain revolving commitments in an aggregate principal amount of $225.0 million, and matures on March 8, 2029. There were no outstanding borrowings under the revolving facilities under the 2021 First Lien Credit Agreement as of March 31, 2026 and December 31, 2025. As of both March 31, 2026 and December 31, 2025, the applicable commitment fee percentage was 0.25% per annum. As of March 31, 2026, the Company was in compliance with the financial covenants contained in the 2021 First Lien Credit Agreement.

On January 8, 2026, LivaNova paid $95.9 million in an early repayment of the remaining amount outstanding under the Term Facilities in full. The early repayment resulted in the recognition of a loss on debt extinguishment of $0.9 million for the three months ended March 31, 2026, associated with the write-off of the remaining unamortized debt issuance costs, and is included within interest expense in the condensed consolidated statements of income (loss).

13

2029 Notes

The effective interest rate of the 2029 Notes was 9.84% as of March 31, 2026. The unamortized debt discount and issuance costs related to the 2029 Notes as of March 31, 2026 and December 31, 2025 were $64.8 million and $69.4 million, respectively. As of March 31, 2026, the conditions for conversion were not met. The Company included its obligations from the 2029 Notes and the associated embedded derivative as long-term liabilities in the condensed consolidated balance sheet as of March 31, 2026, and the 2029 Notes are not convertible for the three months ending June 30, 2026. For additional information regarding the 2029 Notes, refer to LivaNova’s 2025 Form 10-K.

Note 5. Commitments and Contingencies

Saluggia Site Hazardous Substances

LSM, formerly a subsidiary of Sorin, one of the companies that merged into LivaNova PLC in 2015, manages site services for the campus in Saluggia, Italy. In addition to being a former LivaNova manufacturing facility, the Saluggia campus is also the location of manufacturing facilities of third parties, a cafeteria for workers, and storage facilities for hazardous substances and equipment previously used in a nuclear research center, later turned nuclear medicine business, between the 1960s and the late 1990s. Pursuant to authorization from the Italian government, LSM performs ordinary maintenance, secures the facilities, monitors air and water quality, and files applicable reports with the competent environmental authorities.

In 2020, LSM received correspondence from ISIN requesting that, within five years, LSM demonstrate the financial capacity to meet its obligations under Italian law to clean and dismantle any contaminated buildings and equipment, as well as to deliver hazardous substances to a national repository. The national repository will be built by the Italian government at a location and time yet to be determined. ISIN subsequently published Technical Guide n. 30, which identifies the technical criteria and general safety and protection requirements for the design, construction, operation, and dismantling of temporary storage facilities for the hazardous substances.

Although there is no legal obligation to deliver any hazardous substances, as the performance of these obligations is contingent on the construction of the as-yet unbuilt national repository, based on the aforementioned factors, the Company concluded its obligation to clean, dismantle, and deliver any hazardous substances to a national repository is probable and reasonably estimable. The estimated liability as of March 31, 2026 was $41.0 million (€35.5 million), which represented the estimated low end of the range of loss, with an estimated maximum end of the range of loss of $54.6 million (€47.3 million). The estimated liability as of December 31, 2025 was $41.8 million (€35.6 million).

SNIA Environmental Litigation

Sorin was created as a result of a spin-off from SNIA in 2004. SNIA subsequently became insolvent, and the Public Administrations sought compensation from SNIA in an aggregate amount of approximately $4.0 billion for remediation costs relating to the environmental damage at chemical sites previously operated by SNIA’s other subsidiaries. In 2012, SNIA filed a civil action against Sorin in the Civil Court of Milan, asserting joint liability of a parent and a spun-off company; the Public Administrations entered voluntarily into the proceeding, asking Sorin, as jointly liable with SNIA, to pay compensation for SNIA’s environmental damages. In 2015, Sorin was merged into LivaNova.

In 2016, the Court of Milan dismissed all legal actions of SNIA and of the Public Administrations, further requiring the Public Administrations to pay Sorin €292,000 ($336,677 as of March 31, 2026) for legal fees. The Public Administrations appealed the 2016 Decision to the Court of Appeal. In March 2019, the Court of Appeal issued a partial decision on the merits declaring LivaNova jointly liable with SNIA for SNIA’s environmental liabilities in an amount up to the fair value of the net worth received by Sorin because of the spin-off of Sorin from SNIA in 2004, an estimated €572.1 million ($659.6 million as of March 31, 2026). LivaNova appealed the partial decision on liability to the Italian Supreme Court in August 2019.

In 2021, the Court of Appeal delivered the remainder of its decision, ordering LivaNova to pay damages of €453.6 million ($523.0 million as of March 31, 2026). LivaNova appealed the decision on damages in December 2021. In February 2022, the Court of Appeal notified the Company that it granted the Company a suspension with respect to the payment of damages until a decision was reached on the appeal to the Italian Supreme Court, subject to LivaNova providing a first demand bank guarantee of €270.0 million ($311.3 million as of March 31, 2026); LivaNova delivered the SNIA Litigation Guarantee in March 2022.

In November 2022, the Italian Supreme Court issued a procedural document whereby the Italian Supreme Court referred a question on the interpretation of a European directive on demergers to the ECJ. Specifically, the ordinance asked the ECJ to provide a binding decision as to whether a company resulting from a demerger can be held jointly and severally liable not only for the established liabilities of the demerged company that were articulated at the time of demerger, but also for the environmental liabilities of the demerged company that materialized after the demerger which are derived from actions performed prior to the demerger. In July 2024, the ECJ issued a judgment, stating that a demerged company can be held

14

responsible for liabilities not established prior to a demerger as long as the liabilities derive from the conduct of a demerged company prior to the demerger. The ECJ judgment also states that national law should determine whether liability for damages stemming from conduct after a demerger can be assigned to a demerged company.

On March 14, 2025, the Italian Supreme Court issued its decision in response to all of the appeals of the Company and counter-appeals submitted by the Public Administrations. The Italian Supreme Court determined that LivaNova can be held jointly and severally liable for the established liabilities of SNIA at the time of demerger, as well as the environmental liabilities of the demerged company that materialized after the demerger, which are derived from actions performed prior to the demerger; however, the Italian Supreme Court also ruled that the Company should not be held responsible for certain payments previously approved by the Court of Appeal in the amount of €157.3 million ($181.3 million as of March 31, 2026). The case was referred back to the Court of Appeal to implement the decisions respecting costs and damages in accordance with the judgment of the Italian Supreme Court.

On March 31, 2025, as a result of the decision by the Italian Supreme Court, the SNIA Litigation Guarantee was terminated, and the restriction on the cash deposit held as collateral was released. For additional information on the financing of the guarantee, refer to “Note 11. Supplemental Financial Information.”

On May 15, 2025, as a procedural step, the Public Administrations served the Company with a filing to return the proceedings to the Court of Appeal. In addition to seeking a return of the case to the Court of Appeal, the Public Administrations asserted that the Court of Appeal forgo an examination of the amounts disapproved by the Italian Supreme Court and instead impose costs of €108.8 million ($125.4 million as of March 31, 2026) at a minimum. These assertions are counter to the decision of the Italian Supreme Court’s judgment, which disapproved costs of €157.3 million ($181.3 million as of March 31, 2026). The Public Administrations’ filing is not a legal judgment or demand for payment.

At a hearing on January 28, 2026, the Court of Appeal scheduled a hearing for June 24, 2026 to allow the parties to discuss a possible out-of-court resolution of the matter. Discussions remain ongoing, and there can be no assurance that they will result in a settlement.

As a result of the March 14, 2025 decision by the Italian Supreme Court, the Company recorded a current liability in the first quarter of 2025. As of March 31, 2026, the current liability on the consolidated balance sheet was €337.8 million ($389.5 million), representing the Company’s best estimate inclusive of estimated costs, fees, interest, and taxes. These estimated costs do not include the Company’s legal fees, which are expensed as incurred and included in SG&A in LivaNova’s condensed consolidated statements of income (loss). As of the date of this filing, the Company believes the amount recorded for the SNIA matter remains its best estimate and has determined that it has sufficient resources to satisfy the liability.

Product Liability Litigation

The Company continues to be involved in litigation involving LivaNova’s 3T device. The litigation includes the cases remaining in the federal multi-district litigation in the U.S. District Court for the Middle District of Pennsylvania and various U.S. state courts, as well as claims in jurisdictions outside the United States. As of May 6, 2026, the Company was aware of approximately 60 filed and unfiled claims worldwide. The complaints generally seek damages and other relief based on theories of strict liability, negligence, breach of express and implied warranties, failure to warn, design and manufacturing defect, fraudulent and negligent misrepresentation or concealment, unjust enrichment, and violations of various state consumer protection statutes.

As of March 31, 2026 and December 31, 2025, the provision for these matters was $12.6 million and $15.6 million, respectively. While the amount accrued represents LivaNova’s best estimate for those worldwide filed and unfiled claims of which LivaNova is aware and believes are both probable and estimable at this time, the actual liability for resolution of these matters may vary from the Company’s provision. A provision has not been recorded for any claims where a potential loss is not determined to be probable, or a potential loss or range of potential loss is not reasonably estimable at this time.

15

The following table presents the changes in the litigation provision liability for the three months ended March 31, 2026 (in thousands):

As of December 31, 2025						$	15,602
Payments						(2,835)
Adjustments (1)						15
FX and other						(141)
As of March 31, 2026						12,641
Less: Current portion as of March 31, 2026						9,643
Long-term portion as of March 31, 2026 (2)						$	2,998

(1)Adjustments to the litigation provision are included in other operating expense on the condensed consolidated statements of income (loss).

(2)Included in other long-term liabilities on the condensed consolidated balance sheets.

Italian MedTech Payback Measure

In 2015, the Italian Parliament introduced a law regarding public contracts with the National Healthcare System for the supply of goods and services. In particular, the law introduced a payback measure requiring companies selling medical devices in Italy to repay a percentage of the healthcare expenditures exceeding the regional maximum caps for medical devices. In 2024, the Constitutional Court upheld the payback law, and it entered into force in August 2025. In June 2025, the Italian government introduced a settlement mechanism for 2015-2018 obligations, in which the Company elected to participate. In September 2025, the Company paid €3.5 million ($4.0 million as of March 31, 2026), representing full settlement of its obligations for that period, and reversed the remaining $3.8 million reserve associated with those years. As of March 31, 2026 and December 31, 2025, the Company had a reserve of $13.3 million and $12.8 million, respectively, reflecting its best estimate of the full potential obligation for 2019 to present; however, the actual liability could vary. The reserve is included in accrued liabilities and other in the condensed consolidated balance sheets. Amounts recognized associated with the Italian MedTech payback measure are recorded as a reduction to net revenue in the condensed consolidated statements of income (loss).

Other Matters

LivaNova is the subject of various pending or threatened legal actions and proceedings that arise in the ordinary course of LivaNova’s business. These matters are subject to many uncertainties and outcomes that are not predictable and may not be known for extended periods of time. Since the outcome of these matters cannot be predicted with certainty, the costs associated with them could have a material adverse effect on LivaNova’s consolidated results of operations, financial condition, and/or cash flows.

Note 6. Shareholders’ Equity

The tables below present the condensed consolidated statements of shareholders’ equity as of and for the three months ended March 31, 2026 and 2025 (in thousands):

						Ordinary Shares						Ordinary Shares - Amount						Additional Paid-In Capital						Accumulated Other Comprehensive Income (Loss)						Accumulated Deficit						Treasury Shares						Total Shareholders’ Equity
December 31, 2025						55,535						$	84,564					$	2,254,980					$	7,330					$	(1,145,721)					$	(1,166)					$	1,199,987
Share-based compensation plans						3						—						(224)						—						—						—						(224)
Net income						—						—						—						—						22,294						—						22,294
Other comprehensive loss						—						—						—						(10,731)						—						—						(10,731)
March 31, 2026						55,538						$	84,564					$	2,254,756					$	(3,401)					$	(1,123,427)					$	(1,166)					$	1,211,326
December 31, 2024						54,438						$	83,156					$	2,220,658					$	(80,170)					$	(903,250)					$	(136)					$	1,320,258
Share-based compensation plans						1,003						1,290						3,920						—						—						(1,290)						3,920
Net loss						—						—						—						—						(327,322)						—						(327,322)
Other comprehensive income						—						—						—						37,442						—						—						37,442
March 31, 2025						55,441						$	84,446					$	2,224,578					$	(42,728)					$	(1,230,572)					$	(1,426)					$	1,034,298

16

The tables below present the changes in AOCI, net of tax, for the three months ended March 31, 2026 and 2025 (in thousands):

												Foreign Currency Translation Adjustments (1)
December 31, 2025												$	7,330
Other comprehensive loss before reclassifications, net of tax												(10,731)
Reclassification of amounts from AOCI, net of tax												—
Net current-period other comprehensive loss, net of tax												(10,731)
March 31, 2026												$	(3,401)

(1)Taxes were not provided for foreign currency translation adjustments, as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned.

												Foreign Currency Translation Adjustments (1)
December 31, 2024												$	(80,170)
Other comprehensive income before reclassifications, net of tax												37,442
Reclassification of amounts from AOCI, net of tax												—
Net current-period other comprehensive income, net of tax												37,442
March 31, 2025												$	(42,728)

(1)Taxes were not provided for foreign currency translation adjustments, as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned.

Note 7. Share-Based Incentive Plans

Share-Based Compensation Expense

The following table presents the amounts of share-based compensation expense recognized in LivaNova’s condensed consolidated statements of income (loss) by type of arrangement (in thousands):

												Three Months Ended March 31,
																		2026						2025
Service-based RSUs																		$	4,438					$	3,548
Service-based SARs																		3,085						2,753
Market performance-based RSUs																		168						414
Operating performance-based RSUs																		226						821
Employee share purchase plan																		353						247
																		$	8,270					$	7,783

Share-based compensation granted for the three months ended March 31, 2026, representing potential shares and their weighted average grant date fair values by type, is as follows (shares in thousands, fair value in dollars):

						Three Months Ended March 31, 2026
						Shares						Weighted Average Grant Date Fair Value
Service-based RSUs						533						$	61.27
Performance-based RSUs (1) (2)						188						70.26

(1)Awards cliff vest after three years and are subject to performance conditions, including the rank of LivaNova’s total shareholder return for the three-year period ending December 31, 2028 relative to the total shareholder returns of the S&P Healthcare Equipment Select Constituents index, as well as the achievement of specified cumulative revenue growth and adjusted EPS performance thresholds.

17

(2)Represents shares based on an assumed 100% performance achievement. Performance-based RSU awards have a minimum and maximum possible achievement level of 0% and 200%, respectively.

Note 8. Income Taxes

LivaNova’s effective income tax rate for the three months ended March 31, 2026 and 2025 was 15.8% and (3.7)%, respectively. The changes in the effective tax rates for the three months ended March 31, 2026, compared to the prior year period, were primarily attributable to year-over-year changes in income before income tax in countries with varying statutory tax rates, certain discrete tax items, including the SNIA environmental liability, and changes in valuation allowances.

The OBBBA was enacted in the U.S. on July 4, 2025 and includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions. LivaNova has accounted for the relevant changes within its annual effective tax rate and cash taxes.

The Company considers all available evidence (both positive and negative) in determining whether a valuation allowance is required. Depending on operating results in the future, a release of a valuation allowance could occur within the next 12 months. The timing and amount of the valuation allowance release could vary based on the Company’s assessment of all available evidence.

Note 9. Earnings (Loss) Per Share

The following table presents basic and diluted earnings (loss) per share:

												Three Months Ended March 31,
																		2026						2025
Basic earnings (loss) per share																		$	0.41					$	(6.01)
Diluted earnings (loss) per share																		0.40						(6.01)

The following table presents the reconciliations of net income (loss) and weighted average shares outstanding used in the calculations of basic and diluted earnings (loss) per share (in thousands):

												Three Months Ended March 31,
																		2026						2025
Numerator (1):
Net income (loss) - basic and diluted																		$	22,294					$	(327,322)
Denominator:
Basic weighted average shares outstanding																		54,688						54,421
Add: Dilutive effect of share-based compensation and convertible debt instruments (1) (2)																		1,256						—
Diluted weighted average shares outstanding																		55,944						54,421

(1)For the three months ended March 31, 2026 and 2025, the 2029 Notes were outstanding and potentially dilutive securities but were excluded from the computation of diluted earnings (loss) per share because their effect would have been anti-dilutive.

(2)Excluded from the computation of diluted earnings (loss) per share were shares underlying stock options, SARs, and RSUs totaling 0.1 million and 4.6 million for the three months ended March 31, 2026 and 2025, respectively, because to include them would have been anti-dilutive under the treasury stock method.

Note 10. Segment and Geographic Information

Segment Information

LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation.

LivaNova’s Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including HLMs, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, and provides services related to certain of these products.

18

LivaNova’s Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating DRE and DTD. Neuromodulation products include the VNS Therapy System, which consists of an implantable pulse generator, a lead that connects the generator to the vagus nerve, and other accessories. This segment also includes the design and development of neurostimulation devices for treating OSA.

The following table presents net revenue by operating segment and geographic region (in thousands):

												Three Months Ended March 31,
																		2026						2025
Cardiopulmonary
United States																		$	69,279					$	60,834
Europe (1)																		57,304						44,507
Rest of World (1)																		82,072						70,979
																		208,655						176,320
Neuromodulation
United States																		115,400						108,334
Europe (1)																		18,348						15,194
Rest of World (1)																		18,040						15,365
																		151,788						138,893
Other Revenue (2)																		1,815						1,642
Totals
United States																		184,678						169,164
Europe (1)																		75,652						59,701
Rest of World (1)																		101,928						87,990
																		$	362,258					$	316,855

(1)“Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates.

(2)“Other Revenue” includes rental and site services income not allocated to segments.

LivaNova defines segment income as operating income before restructuring expense, amortization of intangible assets, the Saluggia site provision, merger and integration expense, and other income and expense not allocated to segments. Other income and expense not allocated to segments primarily includes corporate expense and rental income. LivaNova’s CODM is the Company’s CEO, who is regularly provided the results comprising segment income to make strategic business decisions, including, but not limited to, evaluation of the Company’s business portfolio, R&D investment decisions, and consideration of the Company’s organizational structure.

The following table presents a reconciliation of segment income to consolidated income (loss) before income tax (in thousands):

												Three Months Ended March 31,
																		2026						2025
Cardiopulmonary																		$	30,067					$	24,691
Neuromodulation																		44,154						52,353
Segment income																		74,221						77,044
Other expense																		(32,750)						(28,427)
Operating income																		41,471						48,617
SNIA environmental liability expense																		—						(360,393)
Interest expense (1)																		(8,291)						(15,286)
Foreign exchange and other income/(expense)																		(5,695)						11,416
Income (loss) before income tax																		$	27,485					$	(315,646)

19

(1)“Interest expense” includes contractual interest expense associated with LivaNova’s short- and long-term financing arrangements and the amortization of debt discount and issuance costs of $4.8 million and $5.7 million for the three months ended March 31, 2026 and 2025, respectively.

The following table presents the components of segment income, including significant expenses, of LivaNova’s reportable segments (in thousands):

						Cardiopulmonary												Neuromodulation
						Three Months Ended March 31,												Three Months Ended March 31,
						2026						2025						2026						2025
Net revenue						$	208,655					$	176,320					$	151,788					$	138,893
Less:
Cost of sales						100,929						84,920						14,221						13,386
Selling, general, and administrative						59,849						53,959						52,619						47,570
Research and development						17,795						12,044						40,794						25,584
3T litigation provision						15						706						—						—
						$	30,067					$	24,691					$	44,154					$	52,353

The following table presents assets by reportable segment (in thousands):

						March 31, 2026						December 31, 2025
Cardiopulmonary						$	1,046,099					$	1,045,189
Neuromodulation						650,103						639,742
Other assets (1)						820,149						921,122
						$	2,516,351					$	2,606,053

(1)“Other assets” primarily include corporate assets not allocated to segments.

The following table presents capital expenditures by segment (in thousands):

												Three Months Ended March 31,
																		2026						2025
Cardiopulmonary																		$	10,409					$	5,169
Neuromodulation																		8,843						2,033
Other capital expenditures (1)																		4,409						3,102
																		$	23,661					$	10,304

(1)“Other capital expenditures” primarily includes corporate capital expenditures not allocated to segments.

The following table presents changes in the carrying amount of goodwill by reportable segment for the three months ended March 31, 2026 (in thousands):

						Cardiopulmonary						Neuromodulation						Total
December 31, 2025						$	394,086					$	398,754					$	792,840
Foreign currency adjustments						(7,250)						—						(7,250)
March 31, 2026						$	386,836					$	398,754					$	785,590

20

Geographic Information

The following table presents property, plant, and equipment, net by geographic region (in thousands):

						March 31, 2026						December 31, 2025
United States						$	86,404					$	79,499
Europe						152,886						147,303
Rest of World						16,193						15,801
						$	255,483					$	242,603

Note 11. Supplemental Financial Information

The following table presents the components of inventories (in thousands):

						March 31, 2026						December 31, 2025
Raw materials						$	72,313					$	75,800
Work-in-process						18,104						12,875
Finished goods						75,087						76,026
						$	165,504					$	164,701

As of March 31, 2026 and December 31, 2025, inventories included adjustments totaling $19.1 million and $18.0 million, respectively, to record balances at the lower of cost or net realizable value.

The following table presents the components of accrued liabilities and other (in thousands):

						March 31, 2026						December 31, 2025
Legal and professional costs						$	24,616					$	18,396
Italian MedTech payback measure						13,329						12,839
Contract liabilities						16,198						11,510
Operating lease liabilities						8,959						8,788
Royalty accrual						4,824						4,758
Provisions for agents, returns, and other						4,362						5,322
Research and development costs						1,414						1,234
Current derivative liabilities						613						99
Interest payable						234						4,638
Other accrued expenses						28,100						26,989
						$	102,649					$	94,573

As of March 31, 2026 and December 31, 2025, contract liabilities totaling $20.8 million and $17.9 million, respectively, were included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheets.

21

The following table presents the items included in foreign exchange and other income/(expense) on the condensed consolidated statements of income (loss) (in thousands):

												Three Months Ended March 31,
																		2026						2025
Fair value adjustment - 2029 Embedded Derivative (1)																		$	(9,350)					$	14,593
Interest income																		3,552						6,443
Fair value adjustment - 2029 Capped Calls (1)																		1,726						(6,545)
Impairment of investment																		(1,132)						—
FX fluctuations																		(589)						(610)
Investment revaluation - Ceribell, Inc.																		—						(2,614)
Fair value adjustment - 2025 Embedded Derivative (1)																		—						2,041
Fair value adjustment - 2025 Capped Calls (1)																		—						(1,819)
Other																		98						(73)
																		$	(5,695)					$	11,416

(1)Refer to “Note 3. Fair Value Measurements.”

Note 12. New Accounting Pronouncements

The following table presents a description of future adoptions of new ASUs issued by the FASB that may have an impact on LivaNova’s consolidated financial statements when adopted:

Issue Date & Standard

Description

Adoption

Assessment

November 2024 ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses

This ASU requires disclosure in the notes to financial statements of additional information disaggregating specific expense categories underlying certain income statement expense line items, including employee compensation, depreciation, and intangible asset amortization, as well as certain other disclosures to provide enhanced transparency into the nature and function of expenses.

This ASU will be effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. This ASU may be applied on either a prospective or retrospective basis, with early adoption permitted.

LivaNova is currently evaluating the effect this standard will have on the Company’s consolidated financial statements and related disclosures.

September 2025 ASU No. 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software

This ASU updates the cost capitalization threshold for internal-use software development costs by removing all references to software project development stages and providing new guidance on how to evaluate whether the probable-to-complete recognition threshold has been met.

This ASU will be effective for annual periods beginning after December 15, 2027, and interim periods within those annual reporting periods, with early adoption permitted. The transition method may be prospective, modified, or retrospective.

LivaNova is currently evaluating the effect this standard will have on the Company’s consolidated financial statements and related disclosures.

Note 13. Revision of Previously Issued Financial Statements

As discussed in “Note 1. Unaudited Condensed Consolidated Financial Statements,” the Company identified and corrected an immaterial error related to the classification of certain employee costs in the Cardiopulmonary segment between cost of sales and selling, general, and administrative expense in the consolidated statements of income (loss).

The following table presents a summary of the corrections to the impacted financial statement line items in the Company’s financial statements previously issued in the unaudited March 31, 2025 Quarterly Report on Form 10-Q (in thousands):

						Three Months Ended March 31, 2025
						As Previously Reported						Adjustment						As Revised
Cost of sales						$	96,080					$	4,521					$	100,601
Gross profit						220,775						(4,521)						216,254
Selling, general, and administrative						133,667						(4,521)						129,146

22

The following table presents a summary of the corrections to the impacted Cardiopulmonary disaggregated segment income table line items in “Note 10. Geographic and Segment Information” previously included in the unaudited March 31, 2025 Quarterly Report on Form 10-Q (in thousands):

						Three Months Ended March 31, 2025
						As Previously Reported						Adjustment						As Revised
Cost of sales						$	80,399					$	4,521					$	84,920
Selling, general, and administrative						58,480						(4,521)						53,959

23

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and related notes, which appear elsewhere in this Report, and with LivaNova’s 2025 Form 10-K. LivaNova’s discussion and analysis may contain forward-looking statements that involve risks and uncertainties. The Company’s actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under “Risk Factors” in Part I, Item 1A. of LivaNova’s 2025 Form 10-K, as updated and supplemented by LivaNova’s Quarterly Reports on Form 10-Q, including in Part II, Item 1A. and elsewhere in this Report. The accompanying unaudited condensed consolidated financial statements of LivaNova and its consolidated subsidiaries have been prepared in accordance with U.S. GAAP on an interim basis. The capitalized terms used below are defined in the “Definitions” section and in the notes to LivaNova’s condensed consolidated financial statements in this Report.

Description of the Business

LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova’s mission to “create ingenious medical solutions that ignite patient turnarounds.” LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.”

Macroeconomic Environment and Global Supply Chain

The current macroeconomic environment, including FX volatility, inflationary pressures, and geopolitical instability, and global supply chain challenges have impacted and may continue to impact LivaNova’s business, consolidated results of operations, financial condition, and/or cash flows. Furthermore, LivaNova continues to experience logistical, capacity, and labor constraints. However, to date, the Company’s supply of raw materials and the production and distribution of finished products have not been materially affected. The Company continues to respond to such challenges. While LivaNova has business continuity plans in place, the impact of the ongoing challenges the Company is navigating, along with their potential escalation, may adversely affect its business.

In addition, the impact that the imposition of tariffs and changes to global trade policies could have on the Company’s results of operations is uncertain. A significant number of LivaNova’s Cardiopulmonary products and component parts are sourced and produced outside of the U.S., including in Italy and Germany. Similarly, LivaNova manufactures its Neuromodulation products in the U.S., which are then often distributed internationally. For additional information, see “Part I, Item 1A. Risk Factors” of the Company’s 2025 Form 10-K.

Business Segments

LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop, and execute its strategy and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation. For additional information regarding LivaNova’s reportable segments, historical financial information, and its methodology for the presentation of financial results, refer to the condensed consolidated financial statements and accompanying notes of this Report.

Cardiopulmonary

LivaNova’s Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including HLMs, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, and provides services related to certain of these products. In particular, the Cardiopulmonary segment includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies and sensing technology for data-driven decision-making during cardiopulmonary bypass procedures.

Information on the Cardiopulmonary segment that could potentially impact LivaNova’s condensed consolidated financial statements and related disclosures is incorporated by reference to “Note 5. Commitments and Contingencies: Product Liability Litigation” in the condensed consolidated financial statements in this Report.

Neuromodulation

LivaNova’s Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating DRE and DTD, as well as the design and development of neurostimulation devices for treating OSA.

24

The segment’s principal product for DRE and DTD, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the left vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals that enable a treating healthcare professional to set parameters for a patient’s pulse generator. The lead does not need to be removed to replace a generator with a depleted battery.

The Neuromodulation segment also includes devices for the treatment of OSA, which are designed to stimulate the hypoglossal nerve and activate specific tongue and palate muscles to help keep the airway open during sleep. On March 18, 2026, the FDA granted PMA for the aura6000 System for the treatment of adult patients with moderate to severe OSA who have failed, do not tolerate, or are ineligible for first-line therapies, such as positive airway pressure.

Critical Accounting Estimates 

For a discussion of LivaNova’s critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the 2025 Form 10-K. For the three months ended March 31, 2026, there were no material changes to the application of critical accounting policies and estimates previously disclosed in LivaNova’s 2025 Form 10-K.

Results of Operations

The following table presents LivaNova’s condensed consolidated results of operations (in thousands):

												Three Months Ended March 31,
																		2026						2025
Net revenue																		$	362,258					$	316,855
Cost of sales (1)																		118,509						100,601
Gross profit (1)																		243,749						216,254
Operating expenses:
Selling, general, and administrative (1)																		143,568						129,146
Research and development																		58,695						37,879
Other operating expense																		15						612
Operating income																		41,471						48,617
SNIA environmental liability expense																		—						(360,393)
Interest expense																		(8,291)						(15,286)
Foreign exchange and other income/(expense)																		(5,695)						11,416
Income (loss) before income tax																		27,485						(315,646)
Income tax expense																		4,340						11,656
Loss from equity method investments																		(851)						(20)
Net income (loss)																		$	22,294					$	(327,322)

(1)The above table presents revised financial results, as discussed in “Note 1. Unaudited Condensed Consolidated Financial Statements” and “Note 13. Revision of Previously Issued Financial Statements” in the condensed consolidated financial statements in this Report.

25

Net Revenue

The following table presents net revenue by operating segment and geographic region (in thousands):

												Three Months Ended March 31,
																														2026						2025												% Change
Cardiopulmonary
United States																														$	69,279					$	60,834											13.9		%
Europe (1)																														57,304						44,507												28.8		%
Rest of World (1)																														82,072						70,979												15.6		%
																														208,655						176,320												18.3		%
Neuromodulation
United States																														115,400						108,334												6.5		%
Europe (1)																														18,348						15,194												20.8		%
Rest of World (1)																														18,040						15,365												17.4		%
																														151,788						138,893												9.3		%
Other Revenue (2)																														1,815						1,642												10.5		%
Totals
United States																														184,678						169,164												9.2		%
Europe (1)																														75,652						59,701												26.7		%
Rest of World (1)																														101,928						87,990												15.8		%
																														$	362,258					$	316,855											14.3		%

(1)“Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates.

(2)“Other Revenue” includes rental and site services income not allocated to segments.

The following table presents segment income (1) (in thousands):

												Three Months Ended March 31,
																														2026						2025												% Change
Cardiopulmonary																														$	30,067					$	24,691											21.8		%
Neuromodulation																														44,154						52,353												(15.7)		%
																														$	74,221					$	77,044											(3.7)		%

(1)For a reconciliation of segment income to consolidated income (loss) before income tax, refer to “Note 10. Segment and Geographic Information” in the condensed consolidated financial statements in this Report.

Cardiopulmonary

Cardiopulmonary net revenue for the three months ended March 31, 2026 increased 18.3% to $208.7 million compared to the three months ended March 31, 2025, with growth across all regions, driven by Essenz Perfusion System sales, strong consumables demand, and favorable realized price.

Cardiopulmonary segment income for the three months ended March 31, 2026 was $30.1 million, compared to segment income of $24.7 million for the three months ended March 31, 2025. The increase in segment income primarily resulted from an increase in net revenue, as described above.

Neuromodulation

Neuromodulation net revenue for the three months ended March 31, 2026 increased 9.3% to $151.8 million compared to the three months ended March 31, 2025, with growth across all regions, driven by total implant growth and favorable realized price.

Neuromodulation segment income for the three months ended March 31, 2026 was $44.2 million, compared to $52.4 million for the three months ended March 31, 2025. The decrease in segment income primarily resulted from $9.7 million of higher expense from the net unfavorable change in fair value of contingent consideration arrangements associated with the ImThera

26

acquisition, as well as a $5.5 million increase in R&D expense associated with the design and development of neurostimulation devices for treating OSA, partially offset by an increase in net revenue, as described above.

Cost of Sales and Expenses

The following table presents costs and expenses as a percentage of net revenue:

												Three Months Ended March 31,
																								2026						2025						Change
Cost of sales (1)																								32.7		%				31.7		%				1.0		%
Selling, general, and administrative (1)																								39.6		%				40.8		%				(1.2)		%
Research and development																								16.2		%				12.0		%				4.2		%
Other operating expense																								—		%				0.2		%				(0.2)		%

(1)The above table and commentary below present revised financial results, as discussed in “Note 1. Unaudited Condensed Consolidated Financial Statements” and “Note 13. Revision of Previously Issued Financial Statements” in the condensed consolidated financial statements in this Report.

Cost of Sales

Cost of sales consists of direct labor, allocated manufacturing overhead, and the acquisition of raw materials and components.

Cost of sales as a percentage of net revenue was 32.7% for the three months ended March 31, 2026, representing an increase of 1.0 percentage points compared to the three months ended March 31, 2025, primarily due to unfavorable product mix.

Selling, General, and Administrative Expense

SG&A expense consists of sales, marketing, general, and administrative activities.

SG&A expense as a percentage of net revenue was 39.6% for the three months ended March 31, 2026, representing a decrease of 1.2 percentage points compared to the three months ended March 31, 2025, primarily driven by fixed cost leverage.

Research and Development Expense

R&D expense consists of product design and development efforts, clinical study programs, and regulatory activities.

R&D expense as a percentage of net revenue was 16.2% for the three months ended March 31, 2026, representing an increase of 4.2 percentage points compared to the three months ended March 31, 2025, primarily due to $8.9 million of higher expense from the net unfavorable change in fair value of the milestone-based contingent consideration arrangement associated with the ImThera acquisition, as well as a $5.5 million increase in costs associated with the design and development of neurostimulation devices for treating OSA.

SNIA Environmental Liability Expense

On March 14, 2025, the Italian Supreme Court issued its decision in response to all of the appeals of the Company and counter-appeals submitted by the Public Administrations. The Italian Supreme Court determined that LivaNova can be held jointly and severally liable for the established liabilities of SNIA at the time of demerger, as well as the environmental liabilities of the demerged company that materialized after the demerger, which are derived from actions performed prior to the demerger. As a result of the decision by the Italian Supreme Court, the Company recorded €333.3 million ($360.4 million) as SNIA environmental liability expense for the three months ended March 31, 2025. For additional information, refer to “Note 5. Commitments and Contingencies” in the condensed consolidated financial statements in this Report.

Interest Expense

Interest expense decreased to $8.3 million for the three months ended March 31, 2026, compared to $15.3 million for the three months ended March 31, 2025, primarily due to repayments of the Term Facilities and 2025 Notes. For additional information, refer to “Note 4. Financing Arrangements” in the condensed consolidated financial statements in this Report.

Foreign Exchange and Other Income/(Expense)

Foreign exchange and other income/(expense) consists primarily of gains and losses arising from transactions denominated in a currency different from an entity’s functional currency, FX derivative gains and losses, interest income, changes in the fair value of embedded and capped call derivatives, and gains and losses associated with LivaNova’s investments.

27

Foreign exchange and other income/(expense) was expense of $5.7 million for the three months ended March 31, 2026, compared to income of $11.4 million for the three months ended March 31, 2025. For additional information, refer to “Note 11. Supplemental Financial Information” in the condensed consolidated financial statements in this Report.

Income Tax Expense

LivaNova’s effective income tax rate for the three months ended March 31, 2026 and 2025 was 15.8% and (3.7)%, respectively. The changes in the effective tax rates for the three months ended March 31, 2026, compared to the prior year period, were primarily attributable to year-over-year changes in income before income tax in countries with varying statutory tax rates, certain discrete tax items, including the SNIA environmental liability, and changes in valuation allowances.

The OBBBA was enacted in the U.S. on July 4, 2025 and includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions. LivaNova has accounted for the relevant changes within its annual effective tax rate and cash taxes.

The Company considers all available evidence (both positive and negative) in determining whether a valuation allowance is required. Depending on operating results in the future, a release of a valuation allowance could occur within the next 12 months. The timing and amount of the valuation allowance release could vary based on the Company’s assessment of all available evidence.

Liquidity and Capital Resources

Based on LivaNova’s current business plan, the Company believes that its sources of liquidity, which primarily consist of cash and cash equivalents, future cash generated from operations, and available borrowings under its revolving credit facility, will be sufficient to fund its uses of liquidity, primarily consisting of day-to-day operating expenses, working capital, capital expenditures, acquisition earnouts, commitments and contingencies, including the SNIA environmental liability, and debt service requirements over the twelve-month period beginning from the issuance date of this Report. From time to time, LivaNova may access debt and/or equity markets to optimize its capital structure, raise additional capital, or increase liquidity, as necessary. LivaNova’s liquidity could be adversely affected by the factors affecting future operating results, including those referred to in “Part I, Item 1A. Risk Factors” in the 2025 Form 10-K, as well as “Note 5. Commitments and Contingencies” in the condensed consolidated financial statements in this Report.

LivaNova’s operating and working capital obligations primarily consist of liabilities arising from the normal course of business, including inventory supply contracts, the future settlement of derivative instruments, and future payments of operating leases, as well as contingent consideration arrangements resulting from acquisitions and obligations associated with legal and other accruals.

The following table presents selected financial information related to LivaNova’s liquidity (in thousands):

						March 31, 2026						December 31, 2025
Available Short-term Liquidity
Cash and cash equivalents						$	539,706					$	635,552
Availability under the 2021 First Lien Credit Agreement						225,000						225,000
						$	764,706					$	860,552
Working Capital
Current assets						$	1,014,237					$	1,101,613
Current liabilities						762,478						808,072
						$	251,759					$	293,541
Debt Obligations
Current portion of long-term debt (1)						$	121					$	30,878
Short-term unsecured borrowing arrangements						2,507						594
Current debt obligations						2,628						31,472
Long-term debt obligations (1)						285,160						345,185
						$	287,788					$	376,657

(1)On January 8, 2026, LivaNova made an early repayment of $95.9 million on principal borrowings in full under the Term Facilities.

28

For information on LivaNova’s debt obligations, refer to “Note 4. Financing Arrangements” in the condensed consolidated financial statements in this Report.

Cash Flows

The following table presents net cash, cash equivalents, and restricted cash provided by (used in) operating, investing, and financing activities and the net (decrease) increase in the balance of cash, cash equivalents, and restricted cash (in thousands):

						Three Months Ended March 31,
						2026						2025
Operating activities						$	15,216					$	23,966
Investing activities						(14,580)						(10,628)
Financing activities						(94,245)						(4,421)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash						(2,237)						5,964
Net (decrease) increase in cash, cash equivalents, and restricted cash (1)						$	(95,846)					$	14,881

(1)On March 31, 2025, as a result of the decision by the Italian Supreme Court, the SNIA Litigation Guarantee was terminated, and the restriction on the cash deposit held as collateral was released. For additional information, refer to “Note 5. Commitments and Contingencies” in the condensed consolidated financial statements in this Report.

Operating Activities

Cash provided by operating activities for the three months ended March 31, 2026 decreased by $8.8 million, compared to the same prior year period, primarily due to an increase in annual incentive payouts and higher cash outflows for inventories, partially offset by higher customer collections resulting from an increase in sales, as well as lower payments for professional services.

Investing Activities

Cash used in investing activities for the three months ended March 31, 2026 increased $4.0 million, compared to the same prior year period, primarily due to an increase in purchases of property, plant, and equipment of $3.5 million, principally related to purchases and development of internal-use software.

Financing Activities

Cash used in financing activities for the three months ended March 31, 2026 increased $89.8 million, compared to the same prior year period, primarily resulting from the January 2026 early repayment of the Term Facilities.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

LivaNova is exposed to certain market risks as part of its ongoing business operations, including risks from foreign currency exchange and interest rates, as well as credit risk, that could adversely affect LivaNova’s consolidated results of operations, financial condition, and/or cash flows. The Company manages these risks through regular operating and financing activities and derivative financial instruments. Quantitative and qualitative disclosures about these risks are included in this Report in “Part I, Item 1. Financial Statements, Note 2. Derivatives and Risk Management,” “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in LivaNova’s 2025 Form 10-K in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Part I, Item 1A. Risk Factors.”

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

LivaNova maintains a system of disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. The disclosure controls and procedures are designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including LivaNova’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Applicable SEC rules require an evaluation of the effectiveness of the Company’s disclosure controls and procedures. LivaNova’s management, under the supervision and with the participation of the Company’s CEO and CFO, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period

29

covered by this Report. Based on that evaluation, LivaNova’s CEO and CFO concluded that, as of March 31, 2026, the design and operation of the Company’s disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There have been no changes in LivaNova’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, LivaNova’s internal control over financial reporting.

30

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

For a description of LivaNova’s material pending legal and regulatory proceedings and settlements, refer to “Note 5. Commitments and Contingencies” in the Company’s condensed consolidated financial statements included in this Report.

ITEM 1A. RISK FACTORS

There have been no material changes in LivaNova’s risk factors from those disclosed in Part I, Item 1A of the Company’s 2025 Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

During the quarter ended March 31, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated, or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act).

Disclosure Pursuant to Section 13(r) of the Exchange Act of 1934

Section 13(r) of the Exchange Act requires issuers to disclose in quarterly reports, among other things, certain types of dealings with Iran and other entities, including transactions or dealings with government-owned entities, even when those activities are lawful and do not involve U.S. persons. Two of LivaNova’s non-U.S. subsidiaries currently sell medical devices, including cardiopulmonary and neuromodulation products, to distributors and a non-governmental organization in Iran to support patient care in that country. LivaNova has limited visibility into the identity of the customers of these distributors and non-governmental organizations in Iran. It is possible that their customers include entities, such as government-owned hospitals or sub-distributors that are owned or controlled directly or indirectly by the Iranian government. However, to the best of its knowledge at this time, LivaNova does not have any contracts or commercial arrangements with the Iranian government or other relevant entities.

LivaNova’s gross revenue and net profits attributable to the above-mentioned Iranian activities were $1.6 million and $0.8 million for the three months ended March 31, 2026.

LivaNova believes its activities are consistent with applicable law, including U.S., UK, European Union, and other applicable sanctions laws, though such laws are complex and continue to evolve rapidly. The Company intends to continue its business in Iran.

31

ITEM 6. EXHIBITS

The exhibits marked with the asterisk symbol (*) are filed or furnished (for example, in the case of Exhibit 32.1) with this Report. Exhibits marked with the cross symbol (†), if any, are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

Exhibit Number						Description
31.1*						Certification of the Chief Executive Officer of LivaNova PLC pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*						Certification of the Chief Financial Officer of LivaNova PLC pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*						Certification of the Chief Executive Officer and Chief Financial Officer of LivaNova PLC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*						Interactive Data Files Pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL: (i) the Condensed Consolidated Statements of Income (Loss) for the three months ended March 31, 2026 and 2025, (ii) the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2026 and 2025, (iii) the Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025, and (v) the Notes to the Condensed Consolidated Financial Statements
104*						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

32

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

			LIVANOVA PLC
Date: May 6, 2026			By:			/s/ VLADIMIR MAKATSARIA
						Vladimir Makatsaria
						Chief Executive Officer
						(Principal Executive Officer)

			LIVANOVA PLC
Date: May 6, 2026			By:			/s/ ALEX SHVARTSBURG
						Alex Shvartsburg
						Chief Financial Officer
						(Principal Accounting and Financial Officer)

33

FAQ

How did LivaNova (LIVN) perform financially in Q1 2026?

LivaNova reported net revenue of $362.3 million and net income of $22.3 million for Q1 2026. A year earlier it posted a $327.3 million net loss driven by a large SNIA environmental liability charge, so results reflect a return to normal profitability.

How did LivaNova’s Cardiopulmonary and Neuromodulation segments perform in Q1 2026?

Cardiopulmonary revenue rose to $208.7 million, up 18.3%, supported by Essenz Perfusion System sales and consumables. Neuromodulation revenue increased 9.3% to $151.8 million, driven by implant growth and pricing, though segment income declined due to higher R&D and ImThera contingent consideration.

What is the status of LivaNova’s SNIA environmental liability as of March 31, 2026?

LivaNova recorded a current SNIA environmental liability of €337.8 million (about $389.5 million) as of March 31, 2026. This reflects its best estimate of amounts owed, including estimated costs, fees, interest, and taxes, following the Italian Supreme Court decision and ongoing Court of Appeal proceedings.

What is LivaNova’s liquidity and debt position at the end of Q1 2026?

At March 31, 2026, LivaNova held $539.7 million in cash and cash equivalents and had total debt of $287.8 million. The company also had $225.0 million available under its revolving credit facility and reported working capital of $251.8 million, supporting its stated liquidity outlook.

How did LivaNova’s cash flow change in Q1 2026 compared with Q1 2025?

Net cash provided by operating activities was $15.2 million in Q1 2026 versus $24.0 million a year earlier. The decline mainly reflected higher incentive payouts and inventory outflows, partly offset by stronger customer collections and lower professional services payments, while capital expenditures increased to $23.7 million.

What regulatory milestone did LivaNova achieve for its sleep apnea therapy in early 2026?

On March 18, 2026, the FDA granted premarket approval (PMA) for LivaNova’s aura6000 System to treat adult patients with moderate to severe obstructive sleep apnea who have failed, do not tolerate, or are ineligible for first-line therapies such as positive airway pressure.